ArticlePilot and feasibility studies2025
In vivo glycocalyx assessment in aneurysmal subarachnoid hemorrhage patients: protocol for a prospective observational feasibility study.
Article in Pilot and feasibility studies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma Biomarkers of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.Brain sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) is a severe complication linked to prolonged hospitalization, reduced functional outcomes, and increased mortality. Due to a lack of validated biomarkers, its development remains unpredictable, and its management is challenging. The glycocalyx, a glycoprotein layer on the luminal surface of endothelial cells, plays a crucial role in regulating leukocyte adhesion, thrombosis, and vascular permeability. As DCI is thought to result from microthrombosis, inflammation, and oxidative stress, the glycocalyx may be a relevant biomarker for DCI. This study aims to determine the feasibility of in vivo glycocalyx measurements in aSAH patients and to determine how these markers change over time in relation to DCI.
methodsThis prospective observational feasibility study will involve 30 aSAH patients. Glycocalyx thickness will be visualized in vivo using sidestream darkfield (SDF) imaging both sublingually and on the conjunctiva, while glycocalyx breakdown will be quantified ex vivo in blood samples. Measurements will be repeated six times during the first 2-week post-ictus. The primary outcome will be the feasibility of the in vivo glycocalyx measurements assessed as a multidimensional outcome, including technical feasibility, operational feasibility, participant experience, and measurement safety. Mixed model analysis will compare the feasibility of sublingual and conjunctival measurements including variables such as age, sex, neurological status, and patient location during measurement. Secondary outcomes will be the responsiveness of the in vivo glycocalyx measurements to DCI, compared to ex vivo glycocalyx measurements, analyzed using mixed-effects logistic regression. DISCUSSION: Traditionally, the search for DCI biomarkers has focused on systemic measurements of cerebrovascular breakdown products, which may vary due to metabolism and renal or hepatic clearance. In vivo assessment of the glycocalyx by SDF imaging is a minimally invasive method that allows for direct, local, and dynamic evaluation of the microcirculation. Given that the conjunctiva is vascularized by the ophthalmic artery branching off the internal carotid artery, it may better reflect cerebral microvascular changes associated with DCI. If feasible, in vivo glycocalyx measurements could serve as a valuable biomarker for monitoring DCI in aSAH patients, potentially offering superior predictive value compared to systemic measurements of glycocalyx breakdown products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.